To develop RNA medicines targeting a proprietary bundle of tumor antigens, Epitopea is tapping nucleic acid delivery ...

Nearly all the patients with severe SCD treated with the gene-editing therapy reni-cel remained free of VOEs for up to two ...

Novartis has said it will shut down two MorphoSys sites in Germany and the US, with the loss of around 330 jobs, after announcing a major delay to the biotech's lead programme pelabresib.